Oncogenic potential of the extraribosomal functions of RPs

Slides:



Advertisements
Similar presentations
p53 Revealed character as a tumor suppressor gene in 1989.
Advertisements

Gene Regulation in Eukaryotic Cells. Gene regulation is complex Regulation, and therefore, expression of a gene is complex. Regulation of these genes.
Pancreatic Islets within Pancreas. Modulators of Insulin Secretion.
P53 The Master Guardian. R point Cell cycle control involves several checkpoints and checkpoint (molecular breaking) mechanisms.
Advantages of C. elegans: 1. rapid life cycle 2. hermaphrodite
MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.
Chapter 15 Noncoding RNAs. You Must Know The role of noncoding RNAs in control of cellular functions.
Control of Gene Activity Chapter 17. Controlling gene activity Remember to control the cell one must control protein synthesis. Remember to control the.
Studi di immunogenicità in modelli murini Laura Pisapia Giovanna Del Pozzo Napoli, 27 Giugno 2013.
Computational Molecular Biology Biochem 218 – BioMedical Informatics miRNA Regulatory.
SiRNA and Epigenetic Asma Siddique Saloom Aslam Syeda Zainab Ali.
Eukaryotic Gene Regulation
Youngae Lee Identification of microRNA function by target prediction and expression profiling.
Chromatin Structure:  Tightly bound DNA less accessible for transcription  DNA methylation: methyl groups added to DNA; tightly packed;  transcription.
Lecture 8 Ch.7 (II) Eukaryotic Gene Regulation. Control of Gene Expression in Eukaryotes: an overview.
Gene Expression (Epigenetics) Chapter 19. What you need to know The functions of the three parts of an operon. The role of repressor genes in operons.
EUKARYOTIC CELL SIGNALING VII Abnormal Signaling in Cancer Signaling to p53 Dr. Ke Shuai Office: 9-240M Factor Tel: X69168
Mestrado Integrado em Medicina Biologia Celular e Molecular II
Date of download: 7/10/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Basic steps of gene expression—transcription factors regulate.
Long Noncoding RNAs: Cellular Address Codes in Development and Disease
Lung Cancer Tumour Markers
P14/19ARF as Tumor Suppressor
Mouse Double Minute 2 (MDM2)
From: Emerging Roles for MicroRNAs in Perioperative Medicine
miRNA genomic organization, biogenesis and function
p53 function and regulation in normal cells and cancer cells
Chapter 18 Gene Expression.
Regulation of Gene Expression
Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.
MiR-155-5p positively regulates colon cancer cell migration by targeting RhoA 2016 Molecular Biomarkers, Berlin | AMR AL-HAIDARI | Department of Clinical.
Tumor Promoting Inflammation
miR-133a positively regulated p53/p21 pathway.
The Role of Myc A Master Regulator Gone Awry
Another Notch on the belt
Andrea L Kasinski, Frank J Slack  Molecular Therapy - Nucleic Acids 
Regulation of Gene Expression
Florie Borel, Pavlina Konstantinova, Peter L.M. Jansen 
MicroRNAs: regulators of gene expression and cell differentiation
C. Belair, F. Darfeuille, C. Staedel 
A, diagram depicting receptor signaling and nutrient import.
Cancer and the Cell Cycle
P Bodies and the Control of mRNA Translation and Degradation
Transcription Initiation:
A Dead End for MicroRNAs
MicroRNAs: Essential players in the regulation of inflammation
Long Noncoding RNAs: Cellular Address Codes in Development and Disease
MicroRNAs in Liver Disease
MicroRNA Control in the Immune System: Basic Principles
MicroRNA Functions in Stress Responses
MicroRNAs in cancer: biomarkers, functions and therapy
John D. Gordan, Craig B. Thompson, M. Celeste Simon  Cancer Cell 
Alternative and aberrant splicing of MDM2 mRNA in human cancer
Regulatory Nascent Peptides in the Ribosomal Tunnel
MYC on the Path to Cancer
Nat. Rev. Urol. doi: /nrurol
Long Noncoding RNAs and Hepatocellular Carcinoma
Model of translational regulation by PDGFRα.
MicroRNA as Therapeutic Targets for Chronic Wound Healing
The cellular interplay of alternative splicing and RNA-binding proteins. The cellular interplay of alternative splicing and RNA-binding proteins. Alternative.
Schematic representation of signaling pathways modulated by PKD1 in cancer. Schematic representation of signaling pathways modulated by PKD1 in cancer.
MicroRNAs in cancer: biomarkers, functions and therapy
Regulation of p53 by MDM2. p53 and MDM2 form an autoregulatory feedback loop. p53 stimulates the expression of MDM2; MDM2, in turn, inhibits p53 activity.
subunits of hemoglobin in the presence and absence of heme.
Oncoprotein synthesis and mechanism of action of omacetaxine mepesuccinate. Oncoprotein synthesis and mechanism of action of omacetaxine mepesuccinate.
Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. LNCaP,
C-MYC overexpression or growth in serum-containing media induces EMT in HBEC3p53,KRAS. c-MYC overexpression or growth in serum-containing media induces.
Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.
Targeting the CBP–p300 synthetic lethal axis.
Long Noncoding RNAs in Cancer Pathways
Regulation of signaling by wild-type and oncogenic Ras.
Presentation transcript:

Oncogenic potential of the extraribosomal functions of RPs Oncogenic potential of the extraribosomal functions of RPs. A, Under growth conditions, the cell is actively translating. Oncogenic potential of the extraribosomal functions of RPs. A, Under growth conditions, the cell is actively translating. Ribosome biogenesis is highly efficient, and the RPL5–5SRNA–RPL11 complex is rapidly incorporated into mature ribosomes. In this situation, MDM2 is free to bind p53 and promote its degradation. B, Under stress conditions, translation and ribosome biogenesis decrease, leaving the RPL5–5SRNA–RPL11 complex free to sequester MDM2. p53 is therefore stabilized, suppressing the cell cycle and eventually promoting apoptosis. C, RPL11 has been shown to negatively regulate c-MYC by binding c-MYC at the promoter regions of its target genes, thereby inhibiting the recruitment of coactivators such as TRAPP. D, RPL5 and RPL11 have both been shown to associate with c-MYC mRNA to promote its degradation through recruitment of the RISC complex, which includes DICER, AGO2, and TRBP. Sergey O. Sulima et al. Cancer Discov 2017;7:1069-1087 ©2017 by American Association for Cancer Research